



PolyActiva secures \$1.5m CUREator Grant to demonstrate clinical proof of concept with Second Generation Ocular Implant as a treatment for patients with Glaucoma.

Melbourne 7 May 2024: PolyActiva, a clinical-stage ophthalmology company, today announces that it has been awarded a \$1.5m CUREator grant, which has been made available through the Federal Government's Medical Research Future Fund's Early-Stage Translation and Commercialisation Support (ESTAC) funding.

The company will use the grant funding to manufacture clinical trial supply and complete a Phase 1 clinical trial in Australia of PA5346, its second-generation latanoprost-releasing ocular implant designed to deliver 12 months of treatment for patients with glaucoma.

PolyActiva's unique and differentiated Prezia™ drug delivery platform is used to develop injectable ocular implants to treat various ophthalmic conditions. PA5346 is a small biodegradable rod that, once inserted into the eye, is expected to deliver a constant daily dose of latanoprost, a well-established drug known to reduce intraocular pressure (IOP) in patients with ocular hypertension and glaucoma. The goal of this therapy is to lower IOP, thereby reducing the need for patients to use daily drops in their eyes to treat their condition.

PolyActiva's first-generation lead product (PA5108) is demonstrating promising results in Phase 2 clinical trials targeting 6 months of therapy. With the CUREator Grant, PolyActiva aims to demonstrate that its second-generation product PA5346 can extend the time between implant administrations for patients.

"We are delighted to be the recipient of a CUREator Grant for the development of PA5346, which provides us with the opportunity to pursue development of a second clinical candidate in our pipeline of glaucoma treatments. Early data with PA5346 suggests it has the potential to provide 12 months treatment for patients with glaucoma. The CUREator Grant will allow us to determine if this product truly meets that objective" says Vanessa Waddell, CEO of PolyActiva.

"Glaucoma is a chronic condition and the standard of care is daily eye drops. Other long-lasting options can generally only be given once. By contrast, because PolyActiva's implants rapidly biodegrade at the end of the treatment period, we believe that they will be able to be given repeatedly, and that would change the way we manage this eye disease. The market opportunity is significant, with US\$4.5 billion spent per annum on glaucoma treatments", Waddell continues.

PolyActiva is pioneering the next generation of advanced manufacturing in Australia. Beyond the breakthrough PolyActiva achieved with PA5346 lies the capability to produce this patented technology at scale, a significant advantage considering the limited number of countries that could achieve the exacting specifications required for this type of manufacturing.

- ENDS -

About PolyActiva

PolyActiva is an innovative clinical-stage ophthalmology company with a unique proprietary polymeric prodrug technology that enables site-specific, precise, and controlled drug delivery to the eye. Our mission is to become a leader in ophthalmic medicine by providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life.



About CUREator

CUREator is a national biotechnology incubator by Brandon BioCatalyst to support the development of Australian biomedical research and innovations. Funded by the Medical Research Future Fund and Australia's national science agency, CSIRO, CUREator provides grant funding programs for opportunities spanning from discovery to clinical development. Funding is provided like an investor with clear milestone-driven tranches to achieve key value-adding and de-risking development milestones. CUREator works closely with project teams to guide them through the early development phase, offering scientific and commercial expertise and networks to support projects meeting key outcomes.

For more information about CUREator, visit: <https://brandonbiocatalyst.com/cureator/>

About Brandon BioCatalyst and Brandon Capital

Brandon Capital is Australasia's leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK. From early-stage seed investment to expansion capital, and Brandon Capital supports life science companies from proof-of-concept to commercialisation. Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of over 50 leading medical research institutes, investors, and government united by a single purpose: progressing the next generation of medical therapies and technology that improve health and save lives.

www.brandoncapital.vc | www.brandonbiocatalyst.com